ArticleNature biomedical engineering2026
Deep-learning triage of three-dimensional pathology datasets for comprehensive and efficient pathologist assessments.
Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prototype-based AI triage for 3D pathology.bioRxiv : the preprint server for biology · 2026Article
- Scalable 3D cell-interaction analysis via supercell graphs for prostate cancer risk stratification.bioRxiv : the preprint server for biology · 2026Article
- Volumetric Cyclic Immunofluorescence for 3D Spatial Profiling of Immune Structures in Human FFPE Tissue.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
- Update of
Authors and funding
23 authors.
Funding
Abstract
Standard slide-based two-dimensional (2D) histopathology severely undersamples spatially heterogeneous tissue, with each thin 2D section representing <1% of the entire biopsy volume. Recent advances in non-destructive three-dimensional (3D) pathology, such as open-top light-sheet microscopy, enable comprehensive high-resolution imaging of large clinical specimens. Since manual review of these massive and complex 3D datasets is infeasible in clinical practice, we present TRICARE, a deep-learning triage framework that identifies high-risk 2D cross sections within 3D pathology datasets to enable time-efficient pathologist evaluation, which offers a lower-risk route for accelerated adoption by retaining pathologists for final diagnoses. TRICARE assigns risk scores to all 2D levels within a tissue volume by leveraging context from a subset of neighbouring depth levels, outperforming models in which predictions are based on isolated 2D levels. In two use cases-risk stratification based on prostate cancer biopsies and screening for dysplasia/cancer in endoscopic biopsies of Barrett's esophagus-AI-triaged 3D pathology, enabled by TRICARE, demonstrates the potential to improve the detection of high-risk diseases compared with slide-based 2D histopathology while optimizing pathologist workloads.
Identifiers
42587049What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.